A related question is how early should depot injectable antipsychotics

be considered. It is common practice that depot medications are reserved for the more chronic patient who after years of treatment have either failed on other drugs or showed persistent lack of adherence to treatment. However, in order to best take advantage of the “window of therapeutic opportunity”2 presented by recent-onset patients, this practice should be reconsidered. Paradoxically, recent-onset patients appear to be the least adherent, but they are also the most responsive to Inhibitors,research,lifescience,medical treatment, and hence have the most to gain from treatment and probably most to lose from lack of treatment. Despite some attempts,76,77

there are no accurate and clinically applicable markers to predict who will remain in remission despite lack of treatment and who will exacerbate despite treatment. Therefore, Inhibitors,research,lifescience,medical physicians, patients, and their families will have to make treatment decisions in an environment of uncertainty, well aware that some individuals will unnecessarily this website suffer drug-induced adverse Inhibitors,research,lifescience,medical effects.
Patients with schizophrenia use cannabis at higher rates than those of the general population.1-3 This has been reported in chronic patients, and other studies have shown that at the time Inhibitors,research,lifescience,medical of the first psychotic episode, up to 40% of patients already use cannabis.4,5 Although some authors understood these findings as being due to self-medlcatlon of symptoms of schizophrenia, one prospective study from 1987 and four more studies published in 2002 and 2003 found that persons using cannabis were at Increased risk of later suffering from psychosis and/or schizophrenia. Inhibitors,research,lifescience,medical These findings were interpreted by some as indicating

that cannabis use lies upon a causal pathway of later psychosis or schizophrenia. In this paper, we will review these findings, and present an alternative explanation for the association between cannabis use and later Tolmetin schizophrenia. Review of the data The first longitudinal study of the relationship between cannabis use and later schizophrenia utilized data on cannabis use by 50 000 18-year-old recruits Into the Swedish army, and ascertained hospitalization for schizophrenia using a hospitalization registry After a 15-year follow-up, they found that frequent cannabis use (more than 50 times In a lifetime) was associated with a sixfold Increased risk for later hospitalization for schizophrenia. After controlling for possible confounders, the odds ratio (OR) was 2.3.6 This same cohort was later reanalyzed using the same design,7 27 years after cannabis use had been ascertained.